Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination

Xencor Inc

Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.
Plamotamab is Phase 2 ready, having completed Phase 1 enrollment in hematologic cancers in late 2023.
Janssen retains rights to develop B-cell targeting CD28 bispecifics, including JNJ-9401 and JNJ-1493, now in Phase 1.
Two collaboration agreements with Janssen continue; Xencor remains eligible for milestones and royalties on retained CD28 programs.
Xencor has opt-in rights to co-fund development of JNJ-9401 (20%) and JNJ-1493 (15%) upon proof-of-concept.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.